Published in N Engl J Med on November 19, 2013
Clarification of Optimal Anticoagulation Through Genetics (COAG) | NCT00839657
Individualized Administration of Warfarin by Polymorphisms of VKORC1 and CYP2C9 Genes | NCT03797534
Association Between Genetic Variant Scores and Warfarin Effect (AWARE1) | NCT03894878
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med (2013) 2.00
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood (2014) 1.63
Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing. Genet Med (2015) 1.59
Warfarin pharmacogenetics. Trends Cardiovasc Med (2014) 1.57
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc (2015) 1.51
Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy. Clin Pharmacol Ther (2017) 1.39
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.37
Genetic-based prediction of disease traits: prediction is very difficult, especially about the future. Front Genet (2014) 1.12
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics (2015) 1.08
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.06
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.05
Pharmacogenetics and coumarin dosing--recalibrating expectations. N Engl J Med (2013) 0.99
Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med (2014) 0.97
The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J (2014) 0.97
Race influences warfarin dose changes associated with genetic factors. Blood (2015) 0.96
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 0.94
Closing the gap between knowledge and clinical application: challenges for genomic translation. PLoS Genet (2015) 0.94
News from the NIH: potential contributions of the behavioral and social sciences to the precision medicine initiative. Transl Behav Med (2015) 0.94
Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. Circ Cardiovasc Genet (2015) 0.93
An integrated approach to defining genetic and environmental determinants for major clinical outcomes involving vitamin D. Mol Diagn Ther (2014) 0.91
Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol (2015) 0.90
Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol (2015) 0.89
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 0.88
Genetic testing in cardiovascular diseases. Curr Opin Cardiol (2014) 0.88
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics (2014) 0.88
Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. J Investig Med High Impact Case Rep (2016) 0.87
Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing. Proc USENIX Secur Symp (2014) 0.87
Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? Pharmacogenomics (2014) 0.86
Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. PLoS One (2014) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
Pharmacogenomics and adverse drug reactions in children. Front Genet (2014) 0.86
Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile. Clin Kidney J (2014) 0.85
Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice. Dtsch Arztebl Int (2014) 0.83
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers Med (2015) 0.82
Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. Br J Clin Pharmacol (2015) 0.82
Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. Biomed Res Int (2014) 0.81
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation (2015) 0.81
Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J (2015) 0.81
Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J (2015) 0.81
Progress towards the integration of pharmacogenomics in practice. Hum Genet (2014) 0.81
Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 0.81
APOE ε variants increase risk of warfarin-related intracerebral hemorrhage. Neurology (2014) 0.80
Anticoagulation therapy: genotype-guided anticoagulation therapy-the jury is still out. Nat Rev Cardiol (2013) 0.80
Pharmacogenomics, human genetic diversity and the incorporation and rejection of color/race in Brazil. Biosocieties (2015) 0.80
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 0.80
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. Eur J Clin Pharmacol (2015) 0.80
Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J (2014) 0.79
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Precision medicine informatics. J Am Med Inform Assoc (2016) 0.79
Role of pharmacogenetics in public health and clinical health care: a SWOT analysis. Eur J Hum Genet (2016) 0.79
Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics (2016) 0.79
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther (2016) 0.79
A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med (2016) 0.78
Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. Pharmacogenomics (2015) 0.78
Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area. Curr Psychiatry Rev (2014) 0.78
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One (2016) 0.78
Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. Pharmacotherapy (2016) 0.78
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metabol Personal Ther (2015) 0.78
Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression. CPT Pharmacometrics Syst Pharmacol (2014) 0.78
Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience. Pediatr Cardiol (2015) 0.78
Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest (2015) 0.78
Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. Pharmacogenomics J (2015) 0.77
Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements. Int J Med Inform (2015) 0.77
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. Clin Pharmacokinet (2016) 0.77
Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics. Pharmacogenet Genomics (2015) 0.77
Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics (2014) 0.77
Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement. PLoS One (2014) 0.77
Personalized medicine in thrombosis: back to the future. Blood (2016) 0.77
Challenges to integrating pharmacogenetic testing into medication therapy management. J Manag Care Spec Pharm (2015) 0.77
Personalized genomes and cardiovascular disease. Cold Spring Harb Perspect Med (2014) 0.77
Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet (2015) 0.77
Warfarin Dosing Algorithms and the Need for Human Intervention. Am J Med (2015) 0.77
Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med (2017) 0.77
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther (2017) 0.76
Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenet Genomics (2016) 0.76
Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip Rev Syst Biol Med (2015) 0.76
Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists. Pharmgenomics Pers Med (2015) 0.76
Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII. Hippokratia (2015) 0.76
Improved drug therapy: triangulating phenomics with genomics and metabolomics. Hum Genomics (2014) 0.76
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics (2015) 0.76
Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm (2016) 0.76
Do physicians think genomic medicine will be useful for patient care? Per Med (2015) 0.76
New pieces to an old puzzle: identifying the warfarin-binding site that prevents clotting. Nat Struct Mol Biol (2017) 0.75
The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review. PLoS One (2016) 0.75
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine (Baltimore) (2016) 0.75
Predicting prolonged dose titration in patients starting warfarin. Pharmacoepidemiol Drug Saf (2016) 0.75
Pharmacogenetics of heart failure. Curr Opin Cardiol (2014) 0.75
Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. BMC Cardiovasc Disord (2016) 0.75
A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy. PLoS One (2016) 0.75
Clinical Application of Pharmacogenetics: Where are We Now? EJIFCC (2013) 0.75
Implementation of inpatient models of pharmacogenetics programs. Am J Health Syst Pharm (2016) 0.75
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach. Clin Pharmacol Ther (2016) 0.75
Atrial fibrillation. J Biomed Res (2013) 0.75
Pragmatic and Ethical Challenges of Incorporating the Genome into the Electronic Medical Record. Curr Genet Med Rep (2014) 0.75
Opportunities and limitations: the value of pharmacogenetics in clinical practice. Br J Clin Pharmacol (2014) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Mol Psychiatry (2017) 0.75
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol (2010) 5.07
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60
A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation (2012) 3.30
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J (2010) 2.46
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
A randomized controlled trial of genotype-based Coumadin initiation. Genet Med (2011) 2.13
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther (2008) 1.90
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials (2010) 1.72
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68
Pharmacogenetics--tailoring treatment for the outliers. N Engl J Med (2009) 1.50
Debating clinical utility. Public Health Genomics (2010) 1.41
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J (2011) 1.38
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation (2012) 1.26
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol (2010) 1.20
Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Clin Trials (2010) 1.18
Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci (2012) 1.14
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J (2013) 1.14
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA (2009) 13.69
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
The ClinicalTrials.gov results database--update and key issues. N Engl J Med (2011) 9.83
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med (2005) 7.92
Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr (2008) 7.91
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care (2005) 7.73
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell (2009) 7.62
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med (2013) 6.21
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA (2005) 6.10
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99